14 results
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
relies, and expects to continue to relying, on third parties to package, label, store and distribute their investigational product candidates
8-K
EX-1.1
PNT
POINT Biopharma Global Inc.
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
or necessary to make the statements therein not misleading. As of the Time of Sale (as defined below), neither (A) the Time of Sale Disclosure Package … (as defined below) nor (B) any issuer free writing prospectus (as defined below), when considered together with the Time of Sale Disclosure Package
DEF 14A
0im 9yfusx5xa29wvs
28 Apr 22
Definitive proxy
8:36am
424B3
7txks7q
5 Aug 21
Prospectus supplement
4:26pm
S-4/A
EX-10.19
cd441bsmcg6vs i26
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
EX-10.12
8fw6n8a1j8eewne
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4
EX-10.12
53is fq4l2v
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm
8-K
EX-1.1
jbps2h2n7g4s cjk180g
10 Jul 20
Therapeutics Acquisition Corp., Sponsored by RA Capital Management, L.P., Announces Pricing of Upsized $118 Million Initial Public Offering
5:17pm
S-1
EX-1.1
q6ca7bdth0hzi97a
15 Jun 20
IPO registration
5:28pm
- Prev
- 1
- Next